2023The annual report details the company's achievements in sustainability and future plans

Beijing, China; Cambridge, Massachusetts; Basel, Switzerland, April 26, 2024/PRNewswire/ -- BeiGene, Ltd. (NASDAQ: BGNE; Hong Kong Stock Exchange: 06160; Shanghai Stock Exchange: 688235), a global oncology innovation company, today released the “2023 Responsible Business and Sustainability” report, which highlights the company's strategy, progress made with current goals, and how to achieve more positive new goals in the future.

At the time of publication of the report, BeiGene's global business was also growing rapidly. In 2023, the company achieved a milestone - more than 1 million patients worldwide received the BTK inhibitor Baiyuze(zebutinib) and anti-PD-1 antibody bazeam(tirelizumab) treatment. In addition, the company is actively expanding its global business layout, including our flagship production site and clinical R&D center located in the Princeton Western Innovation Park in Hopewell, New Jersey, USA, which is expected to be officially opened in July this year.

John V. Oyler (John V. Oyler), co-founder, chairman and CEO of BeiGene, said, “No matter where they are or what their socioeconomic status is, cancer patients are entitled to high-quality, impactful medicines. However, there are still many patients who have to wait years before getting access to medication, or simply cannot afford the price of the medicine. Since its inception, BeiGene has believed in better ways to reduce these barriers and expand the coverage and impact of our medicines, which is why we strategically established our company. We aim to bring medicine to more people faster in a more cost-effective way. Our commitment to innovation goes far beyond what we do in the lab. As a leading global oncology innovation company, BeiGene has always been committed to being a good corporate citizen, and we know we need to work harder for our patients, employees, stakeholders, and even our communities.”

BeiGene's responsible business and sustainability strategy revolves around four key areas: advancing global health, empowering employees, sustainable innovation, and responsible operations. Beginning in 2021, BeiGene is committed to setting goals in various fields and reporting progress every year.

Key Achievements

BeiGene's “Responsible Business and Sustainability” report highlights key results the company has achieved since 2023, including:

• The share of women in positions of vice president and above increased from 33% in 2022 to 38% in 2023.
• A global health equity strategy was developed.
• Employees around the world have volunteered for over 20,000 hours.
• Integrate climate risk into our corporate risk management process.
• Launch a supplier management plan, which will help BeiGene complete the “Scope 3” goal setting by 2025.

Setting the first quantitative climate target

BeiGene knows that human health is closely linked to the health of the planet. As a company focused on improving health and improving health equity, the company remains committed to reducing the environmental impact of its operations.

In 2023, BeiGene announced its first quantitative climate target: by 2026, “Scope 1” and “Scope 2” emissions per unit of self-produced goods (emissions from owned and operated facilities) will be reduced by 25% from 2021.

To achieve climate goals, BeiGene is continuously implementing strategic plans, including energy efficiency improvement projects such as installing solar panels for production sites and renewable energy procurement projects.

Expanding accessibility to patients around the world

Established in early 2023, the BeiGene Foundation is an independent 501 (c) (3) non-profit organization dedicated to removing the barriers that underserved communities around the world face in gaining access to fair and accessible cancer treatment. In the first year of its establishment, the BeiGene Foundation completed its first donation to the Max Foundation. As part of the cooperation between the two parties, the BeiGene Foundation and the Max Foundation will provide Baiyue Ze to adult patients with chronic lymphocytic leukemia in 29 low- and middle-income countries and regions around the world within the next 3 years. This collaboration will fully combine the Max Foundation's professional experience and infrastructure with drugs donated by BeiGene and funds donated by the BeiGene Foundation to further advance the work of both parties in improving access to medicines for patients.

Christine Riley Miller, Global Head of Responsible Business and Sustainability at BeiGene, said: “We are proud that we have made so much progress in our key areas in just a few years. As BeiGe Shenzhou continues to grow, our responsibilities are increasing day by day. We need to maximize positive change and minimize negative impacts on business, society, and the planet. We look forward to continuing on this path.”

For more information on BeiGene's strategy, results, and goals for responsible business and sustainability, click here to access the report.

About BeiGene

BeiGene is a global oncology innovation company focused on developing innovative anti-tumor drugs for cancer patients around the world. Through strong independent research and development capabilities and external strategic cooperation, we continue to accelerate the development of diverse and innovative drug pipelines and product portfolios, and are committed to comprehensively improving drug accessibility and affordability for more patients around the world. We have a team of over 10,000 people across five continents and have established major offices in Beijing, China; Cambridge, MA; and Basel, Switzerland. For more information, please visit or follow the “BeiGene State” WeChat account.

Forward-looking statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 (Private Securities Litigation Reform Act of 1995) and other federal securities laws, including BeiGene's future growth and global expansion, BeiGene's ability to meet the goals set out in the 2023 Responsible Business and Sustainability Report, and BeiGene's plans, commitments, wishes, and goals mentioned under the heading “About BeiGene”. Actual results may differ materially from those in the forward-looking statements due to the influence of various important factors. These factors include: BeiGene's ability to prove the efficacy and safety of its drug candidates; clinical results of drug candidates may not support further development or marketing approval; actions by the pharmacy administration may affect the initiation, schedule, and progress of clinical trials and drug marketing approval; BeiGene's ability to obtain and maintain intellectual property protection for its drugs and technologies; BeiGene's ability to obtain and maintain intellectual property protection for its drugs and technology; BeiGene's reliance on third parties for drug development, production, commercialization, and other services; Baegene Jeju's ability to obtain regulatory approval and commercialization Limited experience with chemical pharmaceutical products, and its ability to obtain further operating capital to complete drug candidate development and achieve and maintain profits; as well as the types of risks discussed more fully in the “Risk Factors” section of the most recent annual report on Form 10-K; and discussions on potential risks, uncertainties, and other important factors in BeiGene's post-period reporting to the US Securities and Exchange Commission. All information in this press release is current only as of the date of publication of the press release, and BeiGene is not responsible for updating such information unless required by law.